复方枸橼酸阿尔维林治疗肠易激综合征的预算影响分析

发布时间：2018-02-15 20:56

本文关键词： 复方枸橼酸阿尔维林肠易激综合征预算影响分析　出处：《中国卫生经济》2015年11期 　论文类型：期刊论文

【摘要】：目的:为了对复方枸橼酸阿尔维林(ACS)治疗肠易激综合征(IBS)进行预算影响分析(BIA),为其报销政策的制定提供参考。方法:采用文献研究的方法,选定P.Ducrotte等在2013年报道的《枸橼酸阿尔维林/西甲硅油按需治疗与常规治疗在肠易激综合征治疗方面的比较:一项随机实用性研究的结果》为原始文献,对其ACS按需治疗组和常规治疗组的成本进行本土化处理,按照中国的患病率和就诊率,在直接成本和总成本口径分别进行BIA。结果:以全部患者都用常规治疗的预算为基数,随着ACS按需治疗人数比例的上升,可以节约的预算也逐步上升,在直接成本和总成本口径最高分别可达377.36亿元(45.90%)和427.87亿元(41.14%)。结论:与常规治疗相比,ACS按需治疗可以大幅度地节约预算,值得纳入报销范围。
[Abstract]:Objective: to analyze the budget impact of compound Alverin citrate (ACS) in the treatment of irritable bowel syndrome (IBS), and to provide a reference for the formulation of reimbursement policy. In 2013, P. Ducrotte et al., A comparison of Alverin citrate / methylsiloxane oil versus conventional therapy in the treatment of irritable bowel syndrome: the results of a randomized and practical study, were selected as the original literature. The cost of ACS on demand treatment group and routine treatment group were treated locally. According to the prevalence rate and the visiting rate in China, the ACS was carried out at the direct cost and the total cost caliber respectively. Results: based on the budget of routine treatment for all patients, As the proportion of people on demand for ACS increases, so does the budget savings. The highest direct cost and total cost can reach thirty-seven billion seven hundred and thirty-six million yuan or 45.90 yuan respectively) and forty-two billion seven hundred and eighty-seven million yuan or 41.14 yuan respectively. Conclusion: compared with conventional treatment, the on-demand treatment can save the budget greatly and is worthy of being included in the reimbursement scope.
【作者单位】：上海应用技术学院;上海市医学科学技术情报研究所上海市卫生发展研究中心;复旦大学公共卫生学院;中国医学科学院北京协和医院;博福益普生制药有限公司;
【分类号】：R574.4

【参考文献】